French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.
from Reuters: Health News https://ift.tt/2U6XNUm
No comments:
Post a Comment